Icosavax Company
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
.png)
Industry:
End-to-end Drug Development
Headquarters:
Seattle, Washington, United States
Founded Date:
2017-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
15
Total Funding:
161000000
Last Funding Date:
2021-04-07
Last Funding Type:
Series B
Register and Claim Ownership